Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30680139 | 1.00 | LRRK2 (0.78) | LRRK2TTK | |
| SCHEMBL30680126 | 0.89 | LRRK2 (0.75) | LRRK2 | |
| SCHEMBL26655331 | 0.89 | LRRK2 (0.75) | LRRK2 | |
| SCHEMBL30680158 | 0.88 | LRRK2 (0.80) | LRRK2TTK | |
| SCHEMBL26655137 | 0.88 | LRRK2 (0.80) | LRRK2TTK | |
| SCHEMBL12065488 | 0.88 | LRRK2 (1.00) | LRRK2TTK | |
| SCHEMBL21855433 | 0.86 | LRRK2 (0.87) | LRRK2TTK | |
| SCHEMBL7446915 | 0.86 | LRRK2 (1.00) | LRRK2TTK | |
| SCHEMBL24042651 | 0.84 | LRRK2 (0.84) | LRRK2TTK | |
| SCHEMBL21938842 | 0.84 | LRRK2 (0.82) | LRRK2TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001875-A1 | AMINOPYRIMIDINYL DERIVATIVES FOR THE TREATMENT OF PARKINSON'S DISEASE | UNIV DUNDEE (GB) | 2026-01-01 | — | — | US | disclosed |
| WO-2023218187-A1 | AMINOPYRIMIDINYL DERIVATIVES FOR THE TREAMENT OF PARKINSON'S DISEASE | UNIVERSITY OF DUNDEE (GB) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023218187-A1 | AMINOPYRIMIDINYL DERIVATIVES FOR THE TREAMENT OF PARKINSON'S DISEASE | UNIVERSITY OF DUNDEE (GB) | 2023-11-16 | — | — | WO | disclosed |
| EP-4276097-A1 | AMINOPYRIMIDINYL DERIVATIVES FOR THE TREAMENT OF PARKINSON'S DISEASE | University Of Dundee (GB) | 2023-11-15 | — | — | EP | disclosed |
| EP-4276097-A1 | AMINOPYRIMIDINYL DERIVATIVES FOR THE TREAMENT OF PARKINSON'S DISEASE | University Of Dundee (GB) | 2023-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001875-A1 | AMINOPYRIMIDINYL DERIVATIVES FOR THE TREATMENT OF PARKINSON'S DISEASE | LRRK2, XIAP, PARK7 | LRRK2 1/4885TTK 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.